Abstract
Patients with renal cell carcinoma (RCC) often develop resistance to antivascular drugs and eventually succumb to disease. However, the underlying molecular mechanism remains poorly understood. In this study, we demonstrated that RASAL2, a RAS GTPase-activating protein, played a tumor-suppressive role in RCC by targeting tumor angiogenesis. Firstly, we showed that RASAL2 was frequently epigenetically silenced in RCC, and its loss was negatively correlated with overall survival of RCC patients. Furthermore, we discovered that RASAL2 could inhibit RCC angiogenesis in vitro and in vivo. Mechanistically, we identified that RASAL2 could activate GSK3β by reducing Ser9 phosphorylation and subsequently decrease the expression of c-FOS and vascular endothelial growth factor A (VEGFA). Interruption of the p-GSK3β/c-FOS pathway with the specific inhibitor or small interfering RNA could reverse the expression of VEGFA, which may provide a new insight to prevent RCC from resistance to antivascular therapy.
References
Dec 17, 2004·Pharmacological Reviews·Ann HoebenErnst A De Bruijn
Mar 10, 2009·Lancet·Brian I RiniBernard Escudier
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Daxing XieJer-Tsong Hsieh
Jun 19, 2012·Seminars in Cancer Biology·Chuan Shen, William G Kaelin
Jun 14, 2013·Kidney International·Rusan CatarAchim Jörres
Jun 26, 2013·Nature Genetics·Yusuke SatoSeishi Ogawa
Sep 14, 2013·Cancer Cell·Sara Koenig McLaughlinKaren Cichowski
Apr 26, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara StefanskaMoshe Szyf
May 13, 2014·Advances in Biological Regulation·Ophélia Maertens, Karen Cichowski
Aug 26, 2014·Current Signal Transduction Therapy·Anna KornakiewiczAnna M Czarnecka
Sep 13, 2014·Oncotarget·Yuting HuangZhi Yao
Nov 11, 2014·The Journal of Clinical Investigation·Min FengQiang Yu
Dec 3, 2014·Biochemical and Biophysical Research Communications·Ning Li, Suyun Li
Aug 20, 2015·Oncotarget·Li QinJianming Xu
Feb 16, 2016·Oncogene·J ZhouJ-T Hsieh
Nov 16, 2016·Targeted Oncology·I DuranO Casanovas
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 17, 2017·Urologic Oncology·Peter J SiskaScott M Haake
Jan 24, 2017·Oncogene·Y ChenL Li
Feb 9, 2017·Cancer Discovery·Rosalie Sears, Joe W Gray
Feb 10, 2017·Cell Death & Disease·Ke HuiKaijie Wu
Apr 28, 2017·Molecular Medicine Reports·Jian-Feng FangShu-Sen Zheng
Apr 30, 2017·Oncology Letters·Zeming JiaZhongfu Xiao
May 4, 2017·The Journal of Experimental Medicine·Ye SunLois E H Smith
Jun 2, 2017·Cancer Research·Simon P RobinsonAndrew R Reynolds
Sep 30, 2017·CA: a Cancer Journal for Clinicians·Pedro C Barata, Brian I Rini
Citations
Jan 29, 2020·Clinical and Experimental Pharmacology & Physiology·Li RenZhiming Hao
Dec 5, 2019·Frontiers in Oncology·Bolun ZhouCaiping Ren
Feb 12, 2020·Journal of Cell Science·Desmond R Harrell Stewart, Geoffrey J Clark
May 16, 2020·Cell Death & Disease·Junfei GuShuyuan Yeh
Nov 25, 2019·EBioMedicine·Xuan WangZhong-Ming Qian
Oct 25, 2020·Cancers·Arianna Bellazzo, Licio Collavin
Nov 27, 2021·Environmental Toxicology·Yuan HuYangwei Fan
Jan 20, 2022·Bioengineered·Sheng HuYing Li